
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing growth in its customer base within both the office-based lab (OBL) and hospital settings, which is contributing to an increase in average selling prices (ASP) for its products. The company's gross margins are being enhanced due to accelerated manufacturing initiatives ahead of a target completion date in January 2026, paired with a favorable revenue mix that leans more towards higher-margin Med-Tech revenues. Management is optimistic about continued growth driven by expanding customer acquisition, increased utilization in existing accounts, and successful pricing strategies.
Bears say
AngioDynamics is facing potential challenges due to projected tariff headwinds ranging from $4 million to $6 million, which could impact profitability. The company anticipates pressure on its inventory in the second half of fiscal year 2026 resulting from increases in raw material prices. Despite some positive performance from capital sales of NanoKnife disposables, these factors raise concerns about the company’s financial stability and future growth prospects.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares